COVID-19 Patient Treated With New ‘Passive Vaccine’; Israeli COVID-19 Treatment With 100% Survival Rate Tested on U.S. Patient

By The Jerusalem Post. A 29-year-old haredi (ultra-Orthodox) coronavirus patient who is being treated at Samson Assuta Ashdod University Hospital has improved from serious to serious but stable condition, after receiving multiple doses of plasma over the weekend from a donor who recovered from coronavirus, a spokesperson for the hospital told The Jerusalem Post.

On Friday, “with the assistance of Health Minister Ya’acov Litzman and his assistant, a suitable donor, a resident of Jerusalem, was found,” explained MDA director-general Eli Bin.

MDA brought her in an ambulance to its blood service center before Shabbat. A special team was waiting for her and transferred the plasma units to the laboratories to perform all required tests and prepare them for transfusion. (Read more from “COVID-19 Patient Treated With Israel’s New ‘Passive Vaccine’” HERE)

______________________________________________________

Israeli COVID-19 Treatment With 100% Survival Rate Tested on U.S. Patient

By The Jerusalem Post. Israeli-based Pluristem has treated its first American patient suffering from COVID-19 complications under the country’s compassionate use program.

The news comes days after a report by the company showed that six critically ill coronavirus patients in Israel who are considered high-risk for mortality were treated with Pluristem’s placenta-based cell-therapy product and survived, according to preliminary data provided by the Haifa-based company.

In the US case, the patient was treated with the company’s PLX cell therapy at Holy Name Medical Center in New Jersey, where Pluristem is already running a Phase III critical limb ischemia study. Like the patients treated in Israel, this patient was critically ill with respiratory failure due to acute respiratory distress syndrome and was intubated in an intensive care unit for three weeks. (Read more from “Israeli COVID-19 Treatment With 100% Survival Rate Tested on U.S. Patient” HERE)

Follow Joe Miller on Twitter HERE and Facebook HERE